When ancient Greek soldiers laid their mythical siege upon the city of Troy, they struggled to break through the city’s impenetrable walls. To finally…
Before Americans become eligible for Medicare at 65, they often rely on private insurance. But for people who start showing signs of Alzheimer’s in…
Anti-amyloid drugs like Leqembi and Kisunla are on the market for treating early Alzheimer’s disease, but they are expensive, difficult to access, and only…
In November of last year, Cassava Sciences announced their experimental Alzheimer’s drug simufilam failed to slow cognitive or functional decline in its 52-week Phase…
European regulators rejected Lilly’s Kisunla citing the number of ARIA-related deaths in its Phase 3 trial. The company will look to appeal the decision….
Eisai and Biogen’s Alzheimer’s drug Leqembi (generic name lecanemab) was the first fully-FDA approved disease-modifying treatment for early-stage Alzheimer’s disease in United States history,…
There currently no cure or treatment that can completely halt or reverse Alzheimer’s pathology in the brain. One of the biggest obstacles: Even after…
With the 2024 FDA approval of Eli Lilly’s Kisunla for early-stage Alzheimer’s disease, there are now two fairly similar anti-amyloid on the market in…
Would you still participate in an Alzheimer’s clinical trial if you found out that because of your genetics, you were more vulnerable to serious…
Alzheimer’s disease is a lot more than memory loss. Many people with the disease develop psychiatric problems like agitation — which are hard to…
Athira Pharma, makers of experimental Alzheimer’s drug fosgonimeton, paid up $4 million to settle a federal case following allegations that the company manipulated scientific…
A recent Science investigation found that Eliezer Masliah, one of the world’s leading Alzheimer’s and Parkinson’s researchers, engaged in research misconduct over the course…
Precision medicine is a medical approach that considers a patient’s genes, environment, and lifestyle. In the realm of Alzheimer’s disease, experts are pushing for…
For decades, scientists blamed Alzheimer’s disease on the buildup of beta-amyloid protein plaques in the brain. But most clinical trials for drugs intended to…
On November 25th, Cassava Sciences announced their experimental Alzheimer’s drug simufilam failed to slow cognitive or functional decline in its 52-week Phase 3 trial….